Seemingly Unrelated Regression Analysis of the Cost and Health-Related Quality of Life Outcomes of the REVAMP Randomized Clinical Trial
(2023) In Value in Health Regional Issues 35. p.42-47- Abstract
Objective: This study aimed to evaluate the 9-month cost and health-related quality of life (HRQOL) outcomes of resistance versus viral load testing strategies to manage virological failure in low-middle income countries. Methods: We analyzed secondary outcomes from the REVAMP clinical trial: a pragmatic, open label, parallel-arm randomized trial investigating resistance versus viral load testing for individuals failing first-line treatment in South Africa and Uganda. We collected resource data, valued according to local cost data and used the 3-level version of EQ-5D to measure HRQOL at baseline and 9 months. We applied seemingly unrelated regression equations to account for the correlation between cost and HRQOL. We conducted... (More)
Objective: This study aimed to evaluate the 9-month cost and health-related quality of life (HRQOL) outcomes of resistance versus viral load testing strategies to manage virological failure in low-middle income countries. Methods: We analyzed secondary outcomes from the REVAMP clinical trial: a pragmatic, open label, parallel-arm randomized trial investigating resistance versus viral load testing for individuals failing first-line treatment in South Africa and Uganda. We collected resource data, valued according to local cost data and used the 3-level version of EQ-5D to measure HRQOL at baseline and 9 months. We applied seemingly unrelated regression equations to account for the correlation between cost and HRQOL. We conducted intention-to-treat analyses with multiple imputation using chained equations for missing data and performed sensitivity analyses using complete cases. Results: For South Africa, resistance testing and opportunistic infections were associated with statistically significantly higher total costs, and virological suppression was associated with lower total cost. Higher baseline utility, higher cluster of differentiation 4 (CD4) count, and virological suppression were associated with better HRQOL. For Uganda, resistance testing and switching to second-line treatment were associated with higher total cost, and higher CD4 was associated with lower total cost. Higher baseline utility, higher CD4 count, and virological suppression were associated with better HRQOL. Sensitivity analyses of the complete-case analysis confirmed the overall results. Conclusion: Resistance testing showed no cost or HRQOL advantage in South Africa or Uganda over the 9-month REVAMP clinical trial.
(Less)
- author
- organization
- publishing date
- 2023-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cost-effectiveness, health economics, resistance testing, seemingly unrelated regression, virological failure
- in
- Value in Health Regional Issues
- volume
- 35
- pages
- 6 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85149451254
- pmid:36863066
- ISSN
- 2212-1099
- DOI
- 10.1016/j.vhri.2022.12.006
- language
- English
- LU publication?
- yes
- id
- 562e0c1e-1a43-4f6c-9653-04f54b5b7213
- date added to LUP
- 2023-04-24 12:13:50
- date last changed
- 2024-06-15 02:07:23
@article{562e0c1e-1a43-4f6c-9653-04f54b5b7213,
abstract = {{<p>Objective: This study aimed to evaluate the 9-month cost and health-related quality of life (HRQOL) outcomes of resistance versus viral load testing strategies to manage virological failure in low-middle income countries. Methods: We analyzed secondary outcomes from the REVAMP clinical trial: a pragmatic, open label, parallel-arm randomized trial investigating resistance versus viral load testing for individuals failing first-line treatment in South Africa and Uganda. We collected resource data, valued according to local cost data and used the 3-level version of EQ-5D to measure HRQOL at baseline and 9 months. We applied seemingly unrelated regression equations to account for the correlation between cost and HRQOL. We conducted intention-to-treat analyses with multiple imputation using chained equations for missing data and performed sensitivity analyses using complete cases. Results: For South Africa, resistance testing and opportunistic infections were associated with statistically significantly higher total costs, and virological suppression was associated with lower total cost. Higher baseline utility, higher cluster of differentiation 4 (CD4) count, and virological suppression were associated with better HRQOL. For Uganda, resistance testing and switching to second-line treatment were associated with higher total cost, and higher CD4 was associated with lower total cost. Higher baseline utility, higher CD4 count, and virological suppression were associated with better HRQOL. Sensitivity analyses of the complete-case analysis confirmed the overall results. Conclusion: Resistance testing showed no cost or HRQOL advantage in South Africa or Uganda over the 9-month REVAMP clinical trial.</p>}},
author = {{Rautenberg, Tamlyn A. and Ng, Shu Kay and George, Gavin and Moosa, Mahomed Yunus S. and McCluskey, Suzanne M. and Gilbert, Rebecca F. and Pillay, Selvan and Aturinda, Isaac and Ard, Kevin L. and Muyindike, Winnie and Musinguzi, Nicholas and Masette, Godfrey and Pillay, Melendhran and Moodley, Pravi and Brijkumar, Jaysingh and Gandhi, Rajesh T. and Johnson, Brent and Sunpath, Henry and Bwana, Mwebesa B. and Marconi, Vincent C. and Siedner, Mark J.}},
issn = {{2212-1099}},
keywords = {{cost-effectiveness; health economics; resistance testing; seemingly unrelated regression; virological failure}},
language = {{eng}},
pages = {{42--47}},
publisher = {{Elsevier}},
series = {{Value in Health Regional Issues}},
title = {{Seemingly Unrelated Regression Analysis of the Cost and Health-Related Quality of Life Outcomes of the REVAMP Randomized Clinical Trial}},
url = {{http://dx.doi.org/10.1016/j.vhri.2022.12.006}},
doi = {{10.1016/j.vhri.2022.12.006}},
volume = {{35}},
year = {{2023}},
}